It is difficult to say what is impossible for the dreams of yesterday are the hopes of today and the reality of tomorrow. - Robert H. Goddard
Posted on: July 04, 2002
In July 2002, Genzyme began the transition of the nine transgenic (rabbit derived enzyme) patients to the CHO derived product. Three of the nine patients (infantile patients in the Netherlands) will remain on the transgenic enzyme until April 2003, when supply will be depleted.
Your generous contribution will go a long way into improving the quality of life of Pompe Disease Patients worldwide.
© 2011 Acid Maltase Deficiency Association
Disclaimer: The AMDA does not endorse any of the products, medications, treatments or information reported herein. The website and its contents is intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.